Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
March 27 2014 - 12:15PM
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP)
today announced that it has created the position of Vice President,
Quality Operations & Regulatory Affairs and has hired industry
veteran, Barbara Ellison, to fill that role. Ms. Ellison has
extensive experience in quality assurance, regulatory compliance,
validation, performance optimization and quality control. Ms.
Ellison will have overall responsibility for Elite's quality and
regulatory functions including the Company's Quality Assurance and
Compliance group and the Analytics and Quality Control
group. Ms. Ellison will serve as a member of Elite's senior
leadership team, reporting directly to Nasrat Hakim, Elite's
President and Chief Executive Officer.
"Barbara is a thirty six year quality and regulatory
professional with exceptional global leadership and pharmaceutical
industry experience. Barbara will oversee the regulatory and
quality functions for Elite and will play a key role for the
Company as it expands the product development and commercialization
of the Company's opioid abuse deterrent products," said Nasrat
Hakim. "Barbara's role was created to support the abuse
deterrent product filings, the first of which is planned for this
year. Barbara will also be an important contributor as Elite
files additional products and launches our first abuse deterrent
product, all planned for next year. As an industry veteran, we
expect that her national and international expertise in quality
management and regulatory affairs will richly support our company's
compliance and quality goals. We welcome her to our team."
Prior to joining Elite, Ellison served as Director of Global
Quality for the Cell Systems Division of Life Technologies,
overseeing the quality and regulatory compliance at ten
manufacturing sites worldwide and overseeing 135
people. Before then, Ms. Ellison was Vice President of Quality
for West Pharmaceutical Services and Site Head of Quality
Operations for Alpharma (now Actavis). She also served in
senior level positions with Novartis as Head of Compliance, Warner
Lambert as Director of Quality Operations and Regulatory
Compliance/Quality Assessment. Ms. Ellison holds a B.S. in
Chemistry and Mathematics from Central Connecticut State
University, New Britain, CT.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and
controlled release products. Elite's strategy includes assisting
partner companies in the life cycle management of products to
improve off-patent drug products and developing generic versions of
controlled release drug products with high barriers to entry. Elite
has seven commercial products currently being sold, twelve
additional approved products pending manufacturing site
transfer and two additional products under review pending approval
by the FDA. Elite's lead pipeline products include abuse
resistant opioids utilizing the Company's patented proprietary
technology, and a once-daily opioid. They are sustained
release oral formulations of opioids for the treatment of chronic
pain, which address two of the limitations of existing oral
opioids: the provision of consistent relief of baseline pain levels
and deterrence of potential abuse. Elite also provides
contract manufacturing for Ascend Laboratories (a subsidiary of
Alkem Laboratories Ltd.) and has partnered with Epic Pharma for the
manufacturing and distribution of eleven approved products pending
manufacturing site, with Hi-Tech Pharmacal to develop an
intermediate for a generic product, and a Hong Kong based company
to develop a branded product for the United States market and its
territories. Elite operates a GMP and DEA registered facility
for research, development, and manufacturing located in Northvale,
NJ.
This news release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Including those related to the effects, if any, on future
results, performance or other expectations that may have some
correlation to the subject matter of this press release, readers
are cautioned that such forward-looking statements involve risks
and uncertainties including, without limitation, its ability to
obtain FDA approval of the transfers of the ANDAs or the timing of
such approval process, delays, uncertainties, inability to obtain
necessary ingredients and other factors not under the control of
Elite, which may cause actual results, performance or achievements
of Elite to be materially different from the results, performance
or other expectations that may be implied by these forward-looking
statements. These risks and other factors, including, without
limitation, the Company's ability to obtain sufficient funding
under the LPC Agreement or from other sources, the timing or
results of pending and future clinical trials, regulatory reviews
and approvals by the Food and Drug Administration and other
regulatory authorities, intellectual property protections and
defenses, and the Company's ability to operate as a going concern,
are discussed in Elite's filings with the Securities and Exchange
Commission, including its reports on forms 10-K, 10-Q and 8-K.
Elite undertakes no obligation to update any forward-looking
statements.
CONTACT: For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2023 to Apr 2024